Yes. Retatrutide reduced liver fat in a randomized phase 2a study of people with obesity and elevated liver fat. The measurement came from liver imaging, so this was more specific than inferring liver improvement from a lower number on the scale.
The finding is promising for metabolic dysfunction-associated steatotic liver disease, or MASLD. It concerns fat content; liver inflammation and scarring are separate questions.
Who was included?
The liver analysis was a substudy of a Retatrutide obesity trial. It included 98 participants whose liver fat was at least 10% at baseline by MRI-PDFF, an imaging method that estimates the proportion of fat in liver tissue.
Participants received different study regimens of Retatrutide or placebo. The prespecified liver endpoint was the relative change in fat content at 24 weeks. Primary liver study.
Starting with elevated liver fat matters: the results describe that group, rather than the effect of taking a product when liver fat is already normal.
What changed at 24 weeks?
The reported average relative reductions were 81.4% in the 8 mg group and 82.4% in the 12 mg group. Placebo showed a 0.3% relative increase. These are study-group labels and outcomes, not a dosing guide.
“Relative reduction” means the change compared with the starting amount of liver fat. It does not mean that participants lost more than 80% of their body weight, or that liver fat fell by 80 percentage points. The amount of liver tissue occupied by fat and the change in that amount are different percentages.
The paper also examined whether liver fat dropped below an imaging threshold. That is a useful way to describe fat normalization, but it does not itself establish that every feature of liver disease has resolved. Indexed primary report.
How does this relate to weight loss?
Liver-fat reduction occurred within an obesity-treatment study, and the authors examined its relationship with changes in weight and other metabolic measures. The liver imaging adds information that a scale cannot provide.
A smaller waist or reduced body weight may be encouraging, but neither tells a person their current liver-fat fraction. Conversely, a liver scan is addressing a different part of metabolic health from appearance.
What a useful follow-up would track
For someone with known fatty liver, the practical goal is an agreed way to follow the liver condition alongside the wider treatment plan. That can involve reviewing the original diagnosis and which measures the clinical team uses over time.
This study gives a clear answer to the title question: Retatrutide substantially lowered measured liver fat in its studied population. Understanding whether inflammation or fibrosis also improves requires the corresponding liver outcomes, rather than assuming they are included in a fat percentage.
Sources & further reading
Educational information. For personal treatment decisions and instructions, consult a qualified clinician or pharmacist with the details of your exact product.
